<p>Neo Ivy Capital Management 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度將其在 Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS - 免費報告）的持股增加了 145.4%。該機構投資者在此期間額外購買了 98,798 股後，持有該公司 166,734 股股票。Hims &amp; Hers Health 約佔 Neo Ivy Capital Management 投資組合的 0.8%，使其成為該投資組合中第 21 大持倉。截止最近一個季度末，Neo Ivy Capital Management 持有的 Hims &amp; Hers Health 的股份約佔 0.08%，價值 4,031,000 美元。</p>
<p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
<ul>
<li>在 UnitedHealth 拋售後，Hims &amp; Hers 的股票會好嗎？</li>
</ul>
<p>其他幾家大型投資者也對 HIMS 的持倉進行了調整。Crewe Advisors LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 28,000 美元。Raleigh Capital Management Inc.在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 1,100.0%。Raleigh Capital Management Inc.現在持有 1,200 股該公司的股票，價值 29,000 美元，此前在上個季度又購買了 1,100 股。Blume Capital Management Inc.在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 100.0%。Blume Capital Management Inc.現在持有 1,200 股該公司的股票，價值 29,000 美元，此前在上個季度又購買了 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 4,415.6%。Smartleaf Asset Management LLC 現在持有 1,445 股該公司的股票，價值 36,000 美元，此前在上個季度又購買了 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 38,000 美元。目前，63.52% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>內部人士下注</h2>
<p>在 Hims &amp; Hers Health 的其他新聞中，首席執行官 Andrew Dudum 在 5 月 16 日星期五出售了 47,534 股該公司的股票。股票以 58.25 美元的平均價格出售，總交易額為 2,768,855.50 美元。出售完成後，首席執行官現在持有 285,194 股該公司的股票，價值 16,612,550.50 美元。這代表其持股減少了 14.29%。該交易在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，內部人士 Patrick Harrison Carroll 在 3 月 18 日星期二出售了 23,287 股該股票。股票以 34.31 美元的平均價格出售，總價值為 798,976.97 美元。出售後，內部人士現在持有 209,661 股該公司的股票，價值約 7,193,468.91 美元。這代表其持倉減少了 10.00%。該出售的披露信息可以在這裏找到。在過去 90 天內，內部人士共出售了 618,936 股公司股票，價值 25,182,692 美元。公司內部人士持有公司股票的 13.71%。</p>
<h2>Hims &amp; Hers Health 股票下跌 7.6%</h2>
<ul>
<li>Hims &amp; Hers 股票圖表顯示強勁的看漲延續</li>
</ul>
<p>Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS）週五開盤價為 53.58 美元。Hims &amp; Hers Health 的 52 周低點為 13.47 美元，52 周高點為 72.98 美元。該股票的市值為 119.9 億美元，市盈率為 121.78，貝塔值為 1.84。該公司的 50 日移動平均線為 37.48 美元，200 日移動平均線為 34.77 美元。</p>
<p>Hims &amp; Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最後一次公佈季度財報是在 5 月 5 日星期一。該公司報告每股收益（EPS）為 0.20 美元，超出市場共識預期的 0.12 美元，超出幅度為 0.08 美元。該公司季度收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。Hims &amp; Hers Health 的股本回報率為 10.97%，淨利潤率為 8.19%。與去年同期相比，Hims &amp; Hers Health 的收入增長了 110.7%。在去年同期，該公司每股收益為 0.05 美元。平均而言，賣方分析師預計 Hims &amp; Hers Health, Inc.在當前財政年度將發佈 0.29 美元的每股收益。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>Hims &amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
<p>多家研究機構最近對 HIMS 進行了評論。華爾街 Zen 在週四的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 上調至 “買入”。Leerink Partners 在 2 月 25 日的研究報告中將 Hims &amp; Hers Health 的目標價格從 24.00 美元上調至 40.00 美元，並給予該股票 “市場表現” 的評級。美國銀行在 4 月 29 日的研究報告中將 Hims &amp; Hers Health 的目標價格從 22.00 美元上調至 26.00 美元，並給予該股票 “表現不佳” 的評級。TD Cowen 在 4 月 29 日的研究報告中將 Hims &amp; Hers Health 的評級從 “買入” 下調至 “持有”，並將該股票的目標價格從 44.00 美元下調至 30.00 美元。最後，Needham &amp; Company LLC 在 5 月 6 日的研究報告中重申了 “買入” 評級，並將 Hims &amp; Hers Health 的目標價格設定為 61.00 美元。兩家股票研究分析師對該股票給予了賣出評級，八家給予了持有評級，四家給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 37.67 美元。</p>
<p><strong>獲取我們關於 Hims &amp; Hers Health 的最新研究報告</strong></p>
<h2>關於 Hims &amp; Hers Health</h2>
<p>（免費報告）</p>
<p>Hims &amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Hims &amp; Hers Health</li>
<li>投資於 5G 技術的頂級股票</li>
<li>NVIDIA 的 AI 機器人躍進：兩隻股票將乘風而起</li>
<li>最具波動性的股票，投資者需要知道什麼</li>
<li>Joby 股票的動盪：近期下跌背後的原因是什麼？</li>
<li>十月值得考慮購買的三隻股票</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

<p>Neo Ivy Capital Management 在第四季度將其在 Hims & Hers Health, Inc. (NYSE:HIMS) 的持股增加了 145.4%，在收購了 98,798 股後，持有 166,734 股。這項投資佔其投資組合的 0.8%。其他投資者也調整了在 HIMS 的持倉。首席執行官 Andrew Dudum 出售了 47,534 股，減少了 14.29% 的持股。Hims & Hers 的股票目前下跌 7.6%，市值為 119.9 億美元，市盈率為 121.78。該公司報告了強勁的收益，超出預期，上一季度每股收益為 0.20 美元，收入為 5.8601 億美元</p>

<p>Neo Ivy Capital Management grew its holdings in Hims &amp; Hers Health, Inc. (NYSE:HIMS - Free Report) by 145.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 166,734 shares of the company's stock after acquiring an additional 98,798 shares during the period. Hims &amp; Hers Health comprises about 0.8% of Neo Ivy Capital Management's investment portfolio, making the stock its 21st biggest position. Neo Ivy Capital Management owned about 0.08% of Hims &amp; Hers Health worth $4,031,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Neo Ivy Capital Management 在最近向證券交易委員會提交的 13F 表格中披露，在第四季度將其在 Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS - 免費報告）的持股增加了 145.4%。該機構投資者在此期間額外購買了 98,798 股後，持有該公司 166,734 股股票。Hims &amp; Hers Health 約佔 Neo Ivy Capital Management 投資組合的 0.8%，使其成為該投資組合中第 21 大持倉。截止最近一個季度末，Neo Ivy Capital Management 持有的 Hims &amp; Hers Health 的股份約佔 0.08%，價值 4,031,000 美元。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims &amp; Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Will Hims &amp; Hers Stock Be Okay After UnitedHealth's Sell-Off?</li>
</ul>
<div class="lb-trans"><ul>
<li>在 UnitedHealth 拋售後，Hims &amp; Hers 的股票會好嗎？</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims &amp; Hers Health in the fourth quarter worth about $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims &amp; Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. lifted its position in shares of Hims &amp; Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of Hims &amp; Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new stake in shares of Hims &amp; Hers Health in the fourth quarter worth about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家大型投資者也對 HIMS 的持倉進行了調整。Crewe Advisors LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 28,000 美元。Raleigh Capital Management Inc.在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 1,100.0%。Raleigh Capital Management Inc.現在持有 1,200 股該公司的股票，價值 29,000 美元，此前在上個季度又購買了 1,100 股。Blume Capital Management Inc.在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 100.0%。Blume Capital Management Inc.現在持有 1,200 股該公司的股票，價值 29,000 美元，此前在上個季度又購買了 600 股。Smartleaf Asset Management LLC 在第四季度將其在 Hims &amp; Hers Health 的持倉提高了 4,415.6%。Smartleaf Asset Management LLC 現在持有 1,445 股該公司的股票，價值 36,000 美元，此前在上個季度又購買了 1,413 股。最後，Summit Securities Group LLC 在第四季度購買了 Hims &amp; Hers Health 的新股份，價值約 38,000 美元。目前，63.52% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Hims &amp; Hers Health news, CEO Andrew Dudum sold 47,534 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $58.25, for a total transaction of $2,768,855.50. Following the completion of the sale, the chief executive officer now owns 285,194 shares in the company, valued at $16,612,550.50. This represents a 14.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. This represents a 10.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 618,936 shares of company stock worth $25,182,692 over the last 90 days. Company insiders own 13.71% of the company's stock.</p>
<div class="lb-trans"><p>在 Hims &amp; Hers Health 的其他新聞中，首席執行官 Andrew Dudum 在 5 月 16 日星期五出售了 47,534 股該公司的股票。股票以 58.25 美元的平均價格出售，總交易額為 2,768,855.50 美元。出售完成後，首席執行官現在持有 285,194 股該公司的股票，價值 16,612,550.50 美元。這代表其持股減少了 14.29%。該交易在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上找到。此外，內部人士 Patrick Harrison Carroll 在 3 月 18 日星期二出售了 23,287 股該股票。股票以 34.31 美元的平均價格出售，總價值為 798,976.97 美元。出售後，內部人士現在持有 209,661 股該公司的股票，價值約 7,193,468.91 美元。這代表其持倉減少了 10.00%。該出售的披露信息可以在這裏找到。在過去 90 天內，內部人士共出售了 618,936 股公司股票，價值 25,182,692 美元。公司內部人士持有公司股票的 13.71%。</p>
</div><h2>Hims &amp; Hers Health Stock Down 7.6%</h2>
<div class="lb-trans"><h2>Hims &amp; Hers Health 股票下跌 7.6%</h2>
</div><ul>
<li>Hims &amp; Hers Stock Chart Points to Strong Bullish Continuation</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票圖表顯示強勁的看漲延續</li>
</ul>
</div><p>Shares of NYSE:HIMS opened at $53.58 on Friday. Hims &amp; Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a market cap of $11.99 billion, a P/E ratio of 121.78 and a beta of 1.84. The business's 50 day moving average is $37.48 and its 200 day moving average is $34.77.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.（紐約證券交易所代碼：HIMS）週五開盤價為 53.58 美元。Hims &amp; Hers Health 的 52 周低點為 13.47 美元，52 周高點為 72.98 美元。該股票的市值為 119.9 億美元，市盈率為 121.78，貝塔值為 1.84。該公司的 50 日移動平均線為 37.48 美元，200 日移動平均線為 34.77 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims &amp; Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims &amp; Hers Health's revenue was up 110.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.05 earnings per share. On average, sell-side analysts anticipate that Hims &amp; Hers Health, Inc. will post 0.29 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最後一次公佈季度財報是在 5 月 5 日星期一。該公司報告每股收益（EPS）為 0.20 美元，超出市場共識預期的 0.12 美元，超出幅度為 0.08 美元。該公司季度收入為 5.8601 億美元，而分析師預期為 5.3521 億美元。Hims &amp; Hers Health 的股本回報率為 10.97%，淨利潤率為 8.19%。與去年同期相比，Hims &amp; Hers Health 的收入增長了 110.7%。在去年同期，該公司每股收益為 0.05 美元。平均而言，賣方分析師預計 Hims &amp; Hers Health, Inc.在當前財政年度將發佈 0.29 美元的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Hims &amp; Hers Stock Rises on Fundamentals and Squeeze Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers 股票因基本面和擠壓潛力而上漲</li>
</ul>
</div><p>A number of research firms recently commented on HIMS. Wall Street Zen upgraded Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Thursday. Leerink Partners boosted their price objective on Hims &amp; Hers Health from $24.00 to $40.00 and gave the stock a &#34;market perform&#34; rating in a research note on Tuesday, February 25th. Bank of America boosted their price objective on Hims &amp; Hers Health from $22.00 to $26.00 and gave the stock an &#34;underperform&#34; rating in a research note on Tuesday, April 29th. TD Cowen cut Hims &amp; Hers Health from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the stock from $44.00 to $30.00 in a research note on Tuesday, April 29th. Finally, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and set a $61.00 price objective on shares of Hims &amp; Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of $37.67.</p>
<div class="lb-trans"><p>多家研究機構最近對 HIMS 進行了評論。華爾街 Zen 在週四的研究報告中將 Hims &amp; Hers Health 的評級從 “持有” 上調至 “買入”。Leerink Partners 在 2 月 25 日的研究報告中將 Hims &amp; Hers Health 的目標價格從 24.00 美元上調至 40.00 美元，並給予該股票 “市場表現” 的評級。美國銀行在 4 月 29 日的研究報告中將 Hims &amp; Hers Health 的目標價格從 22.00 美元上調至 26.00 美元，並給予該股票 “表現不佳” 的評級。TD Cowen 在 4 月 29 日的研究報告中將 Hims &amp; Hers Health 的評級從 “買入” 下調至 “持有”，並將該股票的目標價格從 44.00 美元下調至 30.00 美元。最後，Needham &amp; Company LLC 在 5 月 6 日的研究報告中重申了 “買入” 評級，並將 Hims &amp; Hers Health 的目標價格設定為 61.00 美元。兩家股票研究分析師對該股票給予了賣出評級，八家給予了持有評級，四家給予了買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 37.67 美元。</p>
</div><p><strong>Get Our Latest Research Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Hims &amp; Hers Health 的最新研究報告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.運營一個遠程醫療諮詢平台。它將消費者與醫療專業人員連接，使他們能夠獲得心理健康、性健康、皮膚病學和初級護理的醫療服務。該公司成立於 2017 年，總部位於加利福尼亞州舊金山。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>NVIDIA’s AI Robot Leap: 2 Stocks Set to Ride the Wave</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Turbulence for Joby Shares: What's Behind the Recent Dip?</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Why Carnival Could Be the Ultimate Non-Tech Growth Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Hims &amp; Hers Health</li>
<li>投資於 5G 技術的頂級股票</li>
<li>NVIDIA 的 AI 機器人躍進：兩隻股票將乘風而起</li>
<li>最具波動性的股票，投資者需要知道什麼</li>
<li>Joby 股票的動盪：近期下跌背後的原因是什麼？</li>
<li>十月值得考慮購買的三隻股票</li>
<li>為什麼嘉年華可能是終極非科技增長股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Neo Ivy Capital Management 增加了其在 Hims & Hers Health, Inc.（NYSE:HIMS）的持股量